-+ 0.00%
-+ 0.00%
-+ 0.00%

HLS Therapeutics Q3 EPS $(0.07) Beats $(0.08) Estimate, Sales $14.155M Miss $14.867M Estimate

Benzinga·11/12/2026 12:02:30
Listen to the news
HLS Therapeutics (TSX:HLS) reported quarterly losses of $(0.07) per share which beat the analyst consensus estimate of $(0.08) by 12.5 percent. This is a 41.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $14.155 million which missed the analyst consensus estimate of $14.867 million by 4.79 percent. This is a 4.77 percent increase over sales of $13.511 million the same period last year.